B Lymphocyte News and Research

RSS
Vaccine features that could induce durable humoral immune responses against SARS-CoV-2

Vaccine features that could induce durable humoral immune responses against SARS-CoV-2

Third BNT162b2 dose elicits more durable immune response than second dose

Third BNT162b2 dose elicits more durable immune response than second dose

Diagnostic performance of monocyte distribution width and other leukocyte parameters for SARS-CoV-2 and influenza infection

Diagnostic performance of monocyte distribution width and other leukocyte parameters for SARS-CoV-2 and influenza infection

Is type 1 diabetes likely to rise after the COVID pandemic?

Is type 1 diabetes likely to rise after the COVID pandemic?

SARS-CoV-2 variants are not evolving to escape from T cell-mediated immunity

SARS-CoV-2 variants are not evolving to escape from T cell-mediated immunity

Study assesses the efficacy and safety of lithium treatment in patients infected with severe SARS-CoV-2

Study assesses the efficacy and safety of lithium treatment in patients infected with severe SARS-CoV-2

Evaluating immune protection after third and fourth doses of homologous and heterologous SARS-CoV-2 vaccines among kidney transplant recipients

Evaluating immune protection after third and fourth doses of homologous and heterologous SARS-CoV-2 vaccines among kidney transplant recipients

Understanding sex differences in the pathophysiology of SARS-CoV-2 infection

Understanding sex differences in the pathophysiology of SARS-CoV-2 infection

Review aims to deepen the understanding of the role of natural killer cells in COVID-19

Review aims to deepen the understanding of the role of natural killer cells in COVID-19

Novel transdermal vaccine delivery for COVID-19 and cancer

Novel transdermal vaccine delivery for COVID-19 and cancer

Treg cell Notch receptors drive SARS-CoV-2-induced MIS-C

Treg cell Notch receptors drive SARS-CoV-2-induced MIS-C

Therapies for LGL leukemia should target the immune system, not only cancer cells

Therapies for LGL leukemia should target the immune system, not only cancer cells

Nanocell COVID-19 vaccine elicits potent neutralizing response

Nanocell COVID-19 vaccine elicits potent neutralizing response

Improved seroprevalence and antibody response after third COVID-19 vaccination

Improved seroprevalence and antibody response after third COVID-19 vaccination

Researchers explore the link between immunoglobulins and blood profile in severe SARS-CoV-2 patients

Researchers explore the link between immunoglobulins and blood profile in severe SARS-CoV-2 patients

Study demonstrates cross-neutralization among SARS-CoV-2 Omicron sublineages

Study demonstrates cross-neutralization among SARS-CoV-2 Omicron sublineages

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Divalent SARS-CoV-2 fusion vaccine found to be effective in mice

Divalent SARS-CoV-2 fusion vaccine found to be effective in mice

Is SARS-CoV-2 a Superantigen?

Is SARS-CoV-2 a Superantigen?

CDK6: a potential drug target for severe COVID-19

CDK6: a potential drug target for severe COVID-19

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.